Duodenal tumor risk in Lynch syndrome.


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
02 2019
Historique:
received: 20 07 2018
revised: 09 09 2018
accepted: 04 10 2018
pubmed: 19 11 2018
medline: 14 6 2019
entrez: 19 11 2018
Statut: ppublish

Résumé

Lynch syndrome (LS) is associated with an increased risk of small bowel tumors but routine screening is not recommended in international guidelines. The aim of our study was to determinate the prevalence of duodenal tumors in a French cohort of LS patients. Patients carrying a germline pathogenic variant in a MMR gene, supported by our local network, in which at least one upper endoscopy had been performed, were included. We registered the occurrence of duodenal lesions in those patients. 154 LS patients were identified including respectively 85 MSH2 and 41 MLH1 mutated patients respectively. Seven out of 154 (4.5%) had at least one duodenal lesion. Median age at diagnosis was 58 years (range: 49-73). The twelve lesions locations were: descending duodenum (n = 7), genu inferius (n = 2), duodenal bulb (n = 1), ampulla (n = 1), fourth duodenum (n = 1). Three lesions were invasive adenocarcinomas. The incidence rate of duodenal lesions in patients with MSH2 or MLH1 pathogenic variants was respectively 7.1% (6 out of 85) and 2.4% (1 out of 41) emphasizing a trend toward increased risk of developing duodenal lesion in MSH2 mutated patients: OR: 5.17, IC95% (0.8-60.07), p = 0.1307. Regarding this high prevalence rate, especially in MSH2 patients, regular duodenal screening during upper endoscopy should be considered in routine in LS patients.

Sections du résumé

BACKGROUND AND AIMS
Lynch syndrome (LS) is associated with an increased risk of small bowel tumors but routine screening is not recommended in international guidelines. The aim of our study was to determinate the prevalence of duodenal tumors in a French cohort of LS patients.
METHODS
Patients carrying a germline pathogenic variant in a MMR gene, supported by our local network, in which at least one upper endoscopy had been performed, were included. We registered the occurrence of duodenal lesions in those patients.
RESULTS
154 LS patients were identified including respectively 85 MSH2 and 41 MLH1 mutated patients respectively. Seven out of 154 (4.5%) had at least one duodenal lesion. Median age at diagnosis was 58 years (range: 49-73). The twelve lesions locations were: descending duodenum (n = 7), genu inferius (n = 2), duodenal bulb (n = 1), ampulla (n = 1), fourth duodenum (n = 1). Three lesions were invasive adenocarcinomas. The incidence rate of duodenal lesions in patients with MSH2 or MLH1 pathogenic variants was respectively 7.1% (6 out of 85) and 2.4% (1 out of 41) emphasizing a trend toward increased risk of developing duodenal lesion in MSH2 mutated patients: OR: 5.17, IC95% (0.8-60.07), p = 0.1307.
CONCLUSION
Regarding this high prevalence rate, especially in MSH2 patients, regular duodenal screening during upper endoscopy should be considered in routine in LS patients.

Identifiants

pubmed: 30448460
pii: S1590-8658(18)31179-4
doi: 10.1016/j.dld.2018.10.005
pii:
doi:

Substances chimiques

MLH1 protein, human 0
Protein Subunits 0
MSH2 protein, human EC 3.6.1.3
MutL Protein Homolog 1 EC 3.6.1.3
MutS Homolog 2 Protein EC 3.6.1.3
DNA Repair Enzymes EC 6.5.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-303

Informations de copyright

Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Auteurs

Nassim Hammoudi (N)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France.

Marion Dhooge (M)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France. Electronic address: marion.dhooge@aphp.fr.

Romain Coriat (R)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France; Unité INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Sarah Leblanc (S)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France.

Maximilien Barret (M)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France; Unité INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Benoit Bordacahar (B)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France.

Frederic Beuvon (F)

Digestive Pathology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France.

Frederic Prat (F)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France; Unité INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Fanny Maksimovic (F)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France.

Stanislas Chaussade (S)

Gastroenterology Unit, Cochin University Hospital, Université Paris Descartes, Paris, France; Unité INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH